Akums Drugs and Pharmaceuticals Limited — Others, 14-05-2025: Monitoring Agency Report

Akums Drugs and Pharmaceuticals has announced a board meeting on the financial results for the quarter and half-year. Crisil Ratings confirmed no deviations in the use of IPO proceeds. The company fully utilized Rs 1,599.10 million for debt repayment and Rs 2,270.90 million for subsidiaries’ debt. Incremental working capital of Rs 550 million has been fully deployed, with Rs 197.30 million spent on inorganic growth and Rs 81.40 million remaining. General corporate purpose funds are fully used, while Rs 277.31 million of unutilized proceeds are invested mainly in fixed deposits.